
Dirk BĶhmer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2052967/publications.pdf Version: 2024-02-01



DIDK RÄTHMED

#	Article	IF	CITATIONS
1	Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiotherapy and Oncology, 2007, 84, 121-127.	0.6	272
2	Magnetic nanoparticles for interstitial thermotherapy – feasibility, tolerance and achieved temperatures. International Journal of Hyperthermia, 2006, 22, 673-685.	2.5	243
3	Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991. Journal of Clinical Oncology, 2016, 34, 1748-1756.	1.6	182
4	Guidelines for primary radiotherapy of patients with prostate cancer. Radiotherapy and Oncology, 2006, 79, 259-269.	0.6	139
5	Impact of the filling status of the bladder and rectum on their integral dose distribution and the movement of the uterus in the treatment planning of gynaecological cancer. Radiotherapy and Oncology, 1999, 52, 29-34.	0.6	134
6	High-dose rate interstitial with external beam irradiation for localized prostate cancer – results of a prospective trial. Radiotherapy and Oncology, 1998, 48, 197-202.	0.6	113
7	High Dose Rate (HDR) Brachytherapy with Conformal Radiation Therapy for Localized Prostate Cancer. European Urology, 2005, 47, 441-448.	1.9	69
8	Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death. Journal of Clinical Oncology, 2021, 39, 2284-2293.	1.6	54
9	High Dose Rate Brachytherapy of Localized Prostate Cancer. European Urology, 2002, 41, 420-426.	1.9	49
10	Protection of quality and innovation in radiation oncology: The prospective multicenter trial the German Society of Radiation Oncology (DEGRO-QUIRO study). Strahlentherapie Und Onkologie, 2014, 190, 433-443.	2.0	46
11	Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study. Annals of Oncology, 2010, 21, 2201-2205.	1.2	41
12	Randomized Phase III Trial of Sequential Adjuvant Chemoradiotherapy With or Without Erythropoietin Alfa in Patients With High-Risk Cervical Cancer: Results of the NOGGO-AGO Intergroup Study. Journal of Clinical Oncology, 2011, 29, 3791-3797.	1.6	41
13	Hypofractionated radiotherapy for localized prostate cancer. Strahlentherapie Und Onkologie, 2017, 193, 1-12.	2.0	40
14	MRI before and after external beam intensity-modulated radiotherapy of patients with prostate cancer: The feasibility of monitoring of radiation-induced tissue changes using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence. Radiotherapy and Oncology, 2009, 93, 241-245.	0.6	38
15	Testicular Dose in Prostate Cancer Radiotherapy. Strahlentherapie Und Onkologie, 2005, 181, 179-184.	2.0	35
16	Thermoradiotherapy Using Interstitial Self-Regulating Thermoseeds: An Intermediate Analysis of a Phase II Trial. European Urology, 2004, 45, 574-580.	1.9	34
17	A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study. Annals of Oncology, 2012, 23, 2259-2264.	1.2	34
18	Interstitial Hyperthermia using Self-Regulating Thermoseeds Combined with Conformal Radiation Therapy. European Urology, 2002, 42, 147-153.	1.9	28

Dirk Böhmer

#	Article	IF	CITATIONS
19	Interfraction rotation of the prostate as evaluated by kilovoltage X-ray fiducial marker imaging in intensity-modulated radiotherapy of localized prostate cancer. Medical Dosimetry, 2012, 37, 396-400.	0.9	28
20	Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival. Acta Oncológica, 2018, 57, 362-367.	1.8	28
21	The impact of patient compliance with adjuvant radiotherapy: a comprehensive cohort study. Cancer Medicine, 2013, 2, 712-717.	2.8	27
22	Local ablative treatment for synchronous single organ oligometastatic lung cancer—A propensity score analysis of 180 patients. Lung Cancer, 2018, 125, 164-173.	2.0	27
23	Radiochemotherapy combined with regional pelvic hyperthermia induces high response and resectability rates in patients with nonresectable cervical cancer ≥FIGO IIB "bulky― International Journal of Radiation Oncology Biology Physics, 2006, 66, 1159-1167.	0.8	26
24	The German S3 Guideline Prostate Cancer. Strahlentherapie Und Onkologie, 2010, 186, 531-534.	2.0	26
25	Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy. Strahlentherapie Und Onkologie, 2018, 194, 619-626.	2.0	26
26	Results for local control and functional outcome after linac-based image-guided stereotactic radiosurgery in 190 patients with vestibular schwannoma. Journal of Radiation Research, 2014, 55, 288-292.	1.6	25
27	Dosimetric implications of inter- and intrafractional prostate positioning errors during tomotherapy. Strahlentherapie Und Onkologie, 2017, 193, 700-706.	2.0	25
28	Residual Translational and Rotational Errors after kV X-Ray Image-Guided Correction of Prostate Location Using Implanted Fiducials. Strahlentherapie Und Onkologie, 2010, 186, 544-550.	2.0	24
29	Oligometastases: the new paradigm and options for radiotherapy. Strahlentherapie Und Onkologie, 2013, 189, 357-363.	2.0	23
30	Use of EORTC Target Definition Guidelines for Dose-Intensified Salvage Radiation Therapy for Recurrent Prostate Cancer: Results of the Quality Assurance Program of the Randomized Trial SAKK 09/10. International Journal of Radiation Oncology Biology Physics, 2013, 87, 534-541.	0.8	23
31	Influence of Organ at Risk Definition on Rectal Dose-Volume Histograms in Patients with Prostate Cancer Undergoing External-Beam Radiotherapy. Strahlentherapie Und Onkologie, 2006, 182, 277-282.	2.0	22
32	Ultrahypofractionation of localized prostate cancer. Strahlentherapie Und Onkologie, 2021, 197, 89-96.	2.0	22
33	The impact of <scp>prostateâ€specific antigen</scp> persistence after radical prostatectomy on the efficacy of salvage radiotherapy in patients with primary NO prostate cancer. BJU International, 2019, 124, 785-791.	2.5	20
34	Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy. Strahlentherapie Und Onkologie, 2017, 193, 692-699.	2.0	19
35	Impact of bladder volume on acute genitourinary toxicity in intensity modulated radiotherapy for localized and locally advanced prostate cancer. Strahlentherapie Und Onkologie, 2019, 195, 517-525.	2.0	18
36	Cataract development in patients treated with proton beam therapy for uveal melanoma. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 1625-1630.	1.9	17

Dirk Böhmer

#	Article	IF	CITATIONS
37	Effect of early salvage radiotherapy at PSA < 0.5 ng/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 344-349.	3.9	17
38	Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. European Urology, 2019, 76, 443-449.	1.9	14
39	Role of combined radiation and androgen deprivation therapy in intermediate-risk prostate cancer. Strahlentherapie Und Onkologie, 2020, 196, 109-116.	2.0	14
40	Current standards and future directions for prostate cancer radiation therapy. Expert Review of Anticancer Therapy, 2013, 13, 75-88.	2.4	13
41	Postimplantation Analysis Enables Improvement of Dose–Volume Histograms and Reduction of Toxicity for Permanent Seed Implantation. International Journal of Radiation Oncology Biology Physics, 2008, 71, 28-35.	0.8	11
42	Radiotherapy in nodal oligorecurrent prostate cancer. Strahlentherapie Und Onkologie, 2021, 197, 575-580.	2.0	11
43	Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer. Strahlentherapie Und Onkologie, 2020, 196, 589-597.	2.0	10
44	Radiotherapy and Hormone Treatment in Prostate Cancer. Deutsches Ärzteblatt International, 2016, 113, 235-41.	0.9	9
45	Reirradiation of High-Grade Gliomas: A Retrospective Analysis of 198 Patients Based on the Charité Data Set. Advances in Radiation Oncology, 2020, 5, 959-964.	1.2	7
46	Severe radiotoxicity in an allogeneic transplant recipient with a heterozygous <i><scp>ATM</scp></i> mutation. European Journal of Haematology, 2015, 95, 90-92.	2.2	6
47	Lead-time bias does not falsify the efficacy of early salvage radiotherapy for recurrent prostate cancer. Radiotherapy and Oncology, 2021, 154, 255-259.	0.6	6
48	FDG-PET/CT for pretherapeutic lymph node staging in non-small cell lung cancer: A tailored approach to the ESTS/ESMO guideline workflow. Lung Cancer, 2021, 157, 66-74.	2.0	6
49	Side effects of proton beam therapy of choroidal melanoma in dependence of the dose to the optic disc and the irradiated length of the optic nerve. Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258, 2523-2533.	1.9	5
50	Salvage Radiotherapy versus Observation for Biochemical Recurrence following Radical Prostatectomy for Prostate Cancer: A Matched Pair Analysis. Cancers, 2022, 14, 740.	3.7	5
51	Impact of Dose Escalation on the Efficacy of Salvage Radiotherapy for Recurrent Prostate Cancer—A Risk-Adjusted, Matched-Pair Analysis. Cancers, 2022, 14, 1320.	3.7	5
52	Image-guided intensity-modulated radiotherapy for patients with locally advanced gastric cancer: a clinical feasibility study. Gastric Cancer, 2014, 17, 537-541.	5.3	4
53	Interstitial Hyperthermia Using Thermoseeds in Combination with Conformal Radiotherapy for Localized Prostate Cancer. , 2002, 36, 171-176.		3
54	Validation of Independent Prognostic Value of Asphericity of 18F-Fluorodeoxyglucose Uptake in Non–Small-Cell Lung Cancer Patients Undergoing Treatment With Curative Intent. Clinical Lung Cancer, 2020, 21, 264-272.e6.	2.6	3

Dirk Böhmer

#	Article	IF	CITATIONS
55	Moderately hypofractionated radiotherapy as definitive treatment for localized prostate cancer: Pattern of practice in German-speaking countries. Strahlentherapie Und Onkologie, 2021, 197, 993-1000.	2.0	3
56	Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy. European Urology Oncology, 2021, 4, 301-304.	5.4	2
57	Lacking Evidence to Recommend Neoadjuvant Chemotherapy and Definitive Radiotherapy in Muscle-Invasive Bladder Cancer. Current Oncology Reports, 2021, 23, 18.	4.0	2
58	Need for Androgen Deprivation Therapy in Addition to Definitive Radiation Therapy in Patients With Intermediate-Risk Localized Prostate Cancer. Journal of Clinical Oncology, 2020, 38, 1746-1746.	1.6	1
59	High-Dose Rate Brachytherapy - The Charit� Experience. , 2002, 36, 177-182.		0
60	Assessment of Treatment Techniques and Collimation in Conformal Stereotactic Radiosurgery and Radiotherapy. , 2000, , 206-206.		0
61	In Reply. Deutsches Ärzteblatt International, 2016, 113, 678-679.	0.9	Ο
62	Thymidine phosphorylase induction by ionizing radiation antagonizes 5-fluorouracil resistance in human ductal pancreatic adenocarcinoma. Radiation and Environmental Biophysics, 2022, , 1.	1.4	0